Boston Scientific Corp (BSX, Financial) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Boston Scientific Corp is a developer, manufacturer, and marketer of medical devices. The firm markets its devices to health-care professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. Boston Scientific Corp has a market cap of $55.16 billion; its shares were traded at around $39.86 with a P/E ratio of 33.49 and P/S ratio of 5.78.
For the last quarter Boston Scientific Corp reported a revenue of $2.6 billion, compared with the revenue of $2.4 billion during the same period a year ago. For the latest fiscal year the company reported a revenue of $9.8 billion, an increase of 8.6% from last year. For the last five years Boston Scientific Corp had an average revenue growth rate of 6.9% a year.
The reported diluted earnings per share was $1.19 for the year, an increase of 1387.5% from previous year. The Boston Scientific Corp had a decent operating margin of 16.89%, compared with the operating margin of 16.92% a year before. The 10-year historical median operating margin of Boston Scientific Corp is 13.10%. The profitability rank of the company is 7 (out of 10).
At the current stock price of $39.86, Boston Scientific Corp is traded at 154% premium to its historical median P/S valuation band of $15.69. The P/S ratio of the stock is 5.78, while the historical median P/S ratio is 2.27. The stock gained 47.69% during the past 12 months.
Directors and Officers Recent Trades:
- EVP & President, Rhythm Mgmt Joseph Michael Fitzgerald sold 44,236 shares of BSX stock on 02/12/2019 at the average price of $40. The price of the stock has decreased by 0.35% since.
- EVP,Pres MedSurg David A Pierce sold 5,000 shares of BSX stock on 02/01/2019 at the average price of $38.15. The price of the stock has increased by 4.48% since.
For the complete 20-year historical financial data of BSX, click here.
